Elsevier

Advanced Drug Delivery Reviews

Volume 58, Issue 14, 1 December 2006, Pages 1471-1504
Advanced Drug Delivery Reviews

Recent advances in iron oxide nanocrystal technology for medical imaging

https://doi.org/10.1016/j.addr.2006.09.013Get rights and content

Abstract

Superparamagnetic iron oxide particles (SPIO and USPIO) have a variety of applications in molecular and cellular imaging. Most of the recent research has concerned cellular imaging with imaging of in vivo macrophage activity. According to the iron oxide nanoparticle composition and size which influence their biodistribution, several clinical applications are possible: detection liver metastases, metastatic lymph nodes, inflammatory and/or degenerative diseases. USPIO are investigated as blood pool agents with T1 weighted sequence for angiography, tumour permeability and tumour blood volume or steady-state cerebral blood volume and vessel size index measurements using T2 weighted sequences. Stem cell migration and immune cell trafficking, as well as targeted iron oxide nanoparticles for molecular imaging studies, are at the stage of proof of concept, mainly in animal models.

Introduction

For several years now, research in the field of magnetic resonance imaging (MRI) contrast agents has been directed towards the study and development of superparamagnetic nanoparticles, consisting of iron oxides, magnetite (Fe3O4), maghemite (γFe2O3) or other ferrites, which are insoluble in water [1], [2]. Unlike ferromagnetic substances and because of their size, superparamagnetic agents have no magnetic properties outside an external magnetic field [1]. Superparamagnetic nanoparticles are coated nanocrystals of iron oxides, characterized by a large magnetic moment in the presence of a static external magnetic field [4], [5]. Superparamagnetic nanoparticles are mostly used because of their negative enhancement effect on T2- and T2-weighted sequences. This predominant effect on the T2 relaxation time does not prevent the use of the properties of these agents on the T1 relaxation time when appropriate imaging sequences are chosen [6], [7].

These nanoparticles have in common their specific uptake by the monocyte–macrophage system, explaining why, if they are not entirely captured by the liver and spleen, they are widely evaluated as MRI markers for the diagnosis of inflammatory and degenerative disorders associated with high macrophage phagocytic activity [8].

Two distinct classes of superparamagnetic nanoparticles are currently used for clinical imaging depending on hydrodynamic particle size: superparamagnetic iron oxide (SPIO) particles with a mean particle diameter of more than 50 nm and ultrasmall superparamagnetic iron oxide (USPIO) particles with a smaller hydrodynamic diameter [9].

Two compounds in the SPIO family are commercialized for intravenous use: Ferumoxides (Endorem® – Europe, Feridex® in the USA and Japan) and Ferucarbotran (Resovist® – Europe and Japan). In both cases, the clinical targets are liver tumours. These nanoparticles are medium-sized and coated with dextran (ferumoxides) or carboxydextran (ferucarbotran) [10].

Several USPIO have been investigated in humans for several imaging applications, such as ferumoxtran-10 (dextran) [11], [12], VSOP (citrate) [13], feruglose (pegylated starch) [14] or SHU555C (carboxydextran) [15].

Multiple components determine the efficacy of these agents such as the size of the iron oxide crystals, the charge, the nature of the coating, the hydrodynamic size of the coated particle, etc. These physicochemical characteristics not only affect the efficacy of the superparamagnetic particles in MRI, but also their stability, biodistribution, opsonization and metabolism as well as their clearance from the vascular system.

The chemical coating of these nanoparticles may also allow them to be linked to molecules capable of specifically targeting a specific area such as an organ, a disease or a particular biological system [16], [17]. Furthermore, ex vivo labelling using iron oxide nanoparticles of progenitor and stem cells which can be subsequently tracked in vivo with MRI is a major research subject [18], [19]. These two approaches are under investigation and further developments are needed for large-scale clinical applications.

Section snippets

Chemical composition

Iron oxide nanoparticles are ferrites composed of maghemite and magnetite (Fe2O3, Fe3O4); metal ions in the ferrite crystal occupy two different crystallographic latices in a spinel structure. This crystal structuration results in a net spontaneous magnetization of the iron nanoparticule. Ferrites are characterized by their saturation magnetization at 300 K (92 emug 1 for magnetite and 78 emug 1 for maghemite [20].

Numerous chemical methods can be used to synthesize magnetic nanoparticles for

Superparamagnetism

Bulk ferromagnetic materials are composed of fully magnetized domains the size of a micron. In the absence of an external magnetic field, a ferromagnetic material is not magnetized, as magnetization of these ferromagnetic domains is oriented in several directions. Superparamagnetism occurs when the size of the crystals is smaller than ferromagnetic domains (approximately 30 nm) and, consequently, they do not show any magnetic remanence (i.e. restoration of the induced magnetization to zero upon

Iron oxide nanoparticle imaging

Several clinical applications are possible according to the iron oxide nanoparticle composition and size, which influence their biodistribution (Table 2):

  • -

    SPIO with intense macrophage uptake are used for liver imaging: the healthy liver tissue, which is rich in Kupffer cells (macrophages) phagocytes the SPIO producing a dark signal with a T2/T2 sequence, while no modification of contrast is observed in liver tumours due to the absence of Kupffer cells.

  • -

    USPIO with minor macrophage uptake and

Molecular imaging

Molecular medicine will open up new treatment paradigms for currently untreatable diseases by generating new targets more closely related to pathophysiology. Molecular medicine will also allow more personalized medicine with treatments tailored to the needs of the individual patient.

To fully exploit the new possibilities of molecular medicine, new diagnostic procedures have to be developed, in particular molecular diagnostic compounds and new imaging technologies, such as high-field MRI.

Cellular labelling imaging

Recent progress in the field of stem cells and progenitor cells suggests that these cells could be used, in the near future, to correct or replace defective cell populations. Clinical applications are numerous and promising, both for CNS-related diseases (spinal cord injury, Parkinson's disease, myelin disorders, Huntington's disease, etc) and regeneration of the myocardium. Renal and hepatic diseases may also benefit from progress in cell therapies. The development of these new stem cell-based

Conclusions

Iron oxides now have a variety of applications in molecular and cellular imaging. Most of the recent research has concerned cellular imaging with imaging of in vivo macrophage activity. Stem cell migration and immune cell trafficking, as well as targeted iron oxide nanoparticles for molecular imaging studies, are at the stage of proof of concept, mainly in animal models.

The physicochemical characteristics not only determine the efficacy of the superparamagnetic particles in MRI, but also their

References (228)

  • H.E. Daldrup-Link et al.

    Macromolecular contrast medium Feruglose versus small molecular contrast medium Gadopentetate enhanced magnetic resonance imaging differentiation of benign and malignant breast lesions

    Acad. Radiol.

    (2003)
  • R. Weissleder et al.

    Long circulating iron oxides for MR imaging

    Adv. Drug Deliv. Rev.

    (1995)
  • A. Stroh et al.

    Iron oxide particles for molecular magnetic resonance imaging cause transient oxidative stress in rat macrophages

    Free Radic. Biol. Med.

    (2004)
  • S. Anastase et al.

    Affinity chromatography of human anti-dextran antibodies. Isolation of two distinct populations

    J. Chromatogr., B, Biomed. Sci. Appl.

    (1996)
  • S. Fishbane et al.

    The safety of intravenous iron dextran in hemodialysis patients

    Am. J. Kidney Dis.

    (1996)
  • J. Szebeni

    Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity

    Toxicology

    (2005)
  • D. Pouliquen et al.

    Liver-directed superparamagnetic iron oxide: quantitation of T2-relaxation effects

    Magn. Reson. Imaging

    (1993)
  • W.K. Johnson et al.

    Superparamagnetic iron oxide (SPIO) as an oral contrast agent in gastrointestinal (GI) magnetic resonance imaging (MRI): comparison with state-of-the-art computed tomography (CT)

    Magn. Reson. Imaging

    (1996)
  • D. MacVicar et al.

    Phase III trial of oral magnetic particles in MRI of abdomen and pelvis

    Clin. Radiol.

    (1993)
  • L. Vlahos et al.

    A comparative study between Gd-DTPA and oral magnetic particles (OMP) as gastro-intestinal (GI) contrast agents for MRI of the abdomen

    Magn. Reson. Imaging

    (1994)
  • T.F. Jacobsen et al.

    Oral magnetic particles (ferristene) as a contrast medium in abdominal magnetic resonance imaging

    Acad. Radiol.

    (1996)
  • J.M. Rogers et al.

    Visualization of superior mesenteric lymph nodes by the combined oral and intravenous administration of the ultrasmall superparamagnetic iron oxide AMI-227

    Magn. Reson. Imaging

    (1994)
  • M.F. Bellin et al.

    Iron oxide-enhanced MR lymphography: initial experience

    Eur. J. Radiol.

    (2000)
  • H. Nishimura et al.

    Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10 an ultrasmall superparamagnetic iron oxide

    J. Am. Coll. Surg.

    (2006)
  • B. Arvin et al.

    The role of inflammation and cytokines in brain injury

    Neurosci. Biobehav. Rev.

    (1996)
  • B. Bonnemain

    Superparamagnetic agents in magnetic resonance imaging, physicochemical characteristics and clinical applications. A review

    J. Drug Target.

    (1998)
  • R. Weissleder et al.

    Pharmaceutical iron oxides for MR Imaging

    Rev. Magn. Reson. Med.

    (1992)
  • P.F. Renshaw et al.

    Ferromagnetic contrast agents: a new approach

    Magn. Reson. Med.

    (1986)
  • A. Roch et al.

    Theory of proton relaxation induced by superparamagnetic particles

    J. Chem. Phys.

    (1999)
  • R.N. Muller et al.

    Transverse relaxivity of particulate MRI contrast media: from theories to experiments

    Magn. Reson. Med.

    (1991)
  • C. Corot et al.

    Macrophage imaging in central nervous system and in carotid atherosclerotic plaque imaging using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging

    Invest. Radiol.

    (2004)
  • P. Reimer et al.

    Hepatic MRI with SPIO detection and characterization of focal liver lesions

    Eur. Radiol.

    (1998)
  • O. Clement et al.

    Imaging the lymphatic system possibilities and clinical applications

    Eur. Radiol.

    (2004)
  • M.G. Harisinghani et al.

    Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

    N. Engl. J. Med.

    (2003)
  • S. Wagner et al.

    Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization

    Invest. Radiol.

    (2002)
  • A.M. Taylor et al.

    Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography

    J. Magn. Reson. Imaging

    (1999)
  • B. Tombach et al.

    First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent SH U 555 C results of a human pilot study

    NMR Biomed.

    (2004)
  • R. Weissleder et al.

    Drug targeting in magnetic resonance imaging

    Magn. Reson. Q.

    (1992)
  • J.W. Bulte et al.

    Iron oxide MR contrast agents for molecular and cellular imaging

    NMR Biomed.

    (2004)
  • H.E. Daldrup-Link et al.

    Targeting of hematopoietic progenitor cells with MR contrast agents

    Radiology

    (2003)
  • S. Mornet et al.

    Magnetic nanoparticle design for medical diagnosis and therapy

    J. Mater. Chem.

    (2004)
  • M.L. Lee et al.

    Properties of iron oxide particles in the presence of dextran

    Korean J. Chem. Eng.

    (2002)
  • R. Massart

    Preparation of aqueous magnetic liquids in alkaline and acid media. Abstract

    IEEE Trans. Magn.

    (1981)
  • J. Roger et al.

    Behaviour of aqueous ferrofluids in presence of aminoacids

    Eur. J. Solid State Inorg. Chem.

    (1989)
  • N. Fauconnier et al.

    Adsorption of gluconic and citric acids on maghemite particles in aqueous medium

    Prog. Colloid & Polym. Sci.

    (1996)
  • P.G. De Gennes

    Conformations of polymers attached to an interface

    Macromolecules

    (1980)
  • W. Chu et al.

    Physical and chemical properties of superparamagnetic iron oxide MR contrast agents ferumoxides ferumoxtran ferumoxsil

    Magn. Reson. Imaging

    (1995)
  • M. Rohrer et al.

    Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths

    Invest. Radiol.

    (2005)
  • O. Clement et al.

    Liver imaging with Ferumoxides Feridex fundamentals controversies and practical aspects

    Top. Magn. Reson. Imaging

    (1998)
  • S.J. McLachlan et al.

    Phase I clinical evaluation of a new iron oxide MR contrast agent

    J. Magn. Reson. Imaging

    (1994)
  • Cited by (0)

    This review is part of the Advanced Drug Delivery Reviews theme issue on “Particulate Nanomedicines”, Vol. 58/14, 2006.

    View full text